Kendle International Inc

Kendle International — UBS Global Life Sciences Conference 2008

35 slides from Kendle International's conference presentation, Sep 24, 2008

  1. Slide 1: UBS Global Life Sciences Conference

    UBS Global Life Sciences Conference New York City September 24, 2008 Exhibit 99.1

  2. Slide 2: Safe Harbor

    N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Safe Harbor • Information herein contains forward - looking statements pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. All such forward- looking stat

  3. Slide 3: CRO market opportunity accelerating within a decelerating pharma market

    9.3% Global CRO market growth and global R&D spending exceeding overall pharma market growth 13-15% N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Source: Goldman Sachs, May 20, 2008. Global R&D spending Overall pharma market 6.6% Global CRO m

  4. Slide 4: Our vision: Customer and business expansion

    Customer and business expansion to accelerate growth Operational continuity and leverage via the matrix Infrastructure growth to drive global connectivity Kendle Our vision

  5. Slide 5: Our vision: best-in-class provider of clinical development services

    “Best-in-class” provider of clinical development services to the biopharmaceutical industry through broad therapeutic and geographic expertise N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Our vision

  6. Slide 6: Our vision: Operational continuity and leverage via the matrix

    Kendle Operational continuity and leverage via the matrix Our vision

  7. Slide 7: Best in Class Provider

    Best in Class Provider Therapeutic Expertise Geographic Expertise Kendle High quality driven by Kendle’s 5 Brands Excellence driven by leveraging the matrix of 5 Brands across 5 geographic regions Experience driven by leveraging the matrix of 5 Brands across 5 geographic regions

  8. Slide 8: Our vision: Customer and business expansion to accelerate growth

    Customer and business expansion to accelerate growth Kendle Our vision

  9. Slide 9: Customer Development

    Customer Development Strategic Relationships Full Service Megatrials Execution across global footprint * High customer need: R&D efficiency and Delivery Confidence * High shareholder value: Repeat business and Efficiencies + Growth opportunities « Supports Expansion + Leverage Best-in-class geograph

  10. Slide 10: Customer drivers for R&D efficiency

    N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Source: Jefferies, CRO Survey, March 2007 % of total respondents Vendor relationship management principles Electronic data capture (EDC) Functional outsourcing Preferred provider agreements Centra

  11. Slide 11: Full service megatrials: the need for global capability

    N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a • Geographic reach over five regions • Strong project leadership for large global trials • Workforce needs • Efficiency and productivity through technology Full service megatrials The need for glo

  12. Slide 12: Execution across global footprint: patient access

    Kendle Real people Real sus? Execution across global footprint Patient access Expected development spending Allocation of development spending allocation by 2011; significant increase in Asia/Pacific, Other by global region — 2007 Other Asial 9% Other Pacific: 8% Us. 26% EU 23% ; Us. 60% Asial Pacif

  13. Slide 13: Continuing globalization

    Continuing globalization Kendle Real people Real results Revenue moves away from United States into global markets with a shift from 50% in Q2 2007 to 45% in Q2 2008 92 2007 5%, Latin America grows from 5% of ° total revenue in Q2 2007 to 8% of total revenue in Q2 2008 92 2007 45% 92 2008 92 2008 13

  14. Slide 14: Slide 14

  15. Slide 15: Slide 15

  16. Slide 16: Slide 16

  17. Slide 17: Slide 17

  18. Slide 18: Slide 18

  19. Slide 19: Slide 19

  20. Slide 20: Early Stage Opportunities; Geographic Expansion; Business expansion

    N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Early Stage Opportunities Geographic Expansion Customer and business expansion Business expansion

  21. Slide 21: Preclinical/Phase I opportunity

    N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Preclinical/Phase I opportunity Source: Goldman Sachs, Pharmaceutical Services, Dec 2007 and May 2008 Phase I Compounds in Development by Year, Month Preclinical/Phase I a $9.8 billion market by 2

  22. Slide 22: Shift in opportunity by phase

    N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Shift in opportunity by phase Source: William Blair & Company, CRO Industry Update , Oct. 5, 2007. New compounds in pharmaceutical development, 1995 to present

  23. Slide 23: Early Stage

    N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Early Stage • Phase I growth is expected to outpace broader market at approximately 15-16% annually • Early Stage will grow to approximately 20% of our business over the next 3 years Utrecht Toron

  24. Slide 24: Asia/Pacific

    N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Asia/Pacific • Asia/Pacific growth is estimated at 30-50% through 2013 • Kendle’s focus is expanded breadth and depth of key markets to win and deliver megatrials Current Kendle operations Markets

  25. Slide 25: Our vision: Infrastructure growth to drive global connectivity

    Kendle Our vision Infrastructure growth to drive global connectivity

  26. Slide 26: Infrastructure growth to drive global connectivity

    Kendle Real people Real sults? Infrastructure growth to drive global connectivity Functional Finance, Business orientation Commercial Operations and sophistication Operational ee Bie uncae Leadership Leverage Global connectivity System/Processes Infrastructure/ERP. Beet ae

  27. Slide 27: Financial Profile

    Financial Profile

  28. Slide 28: Delivering value for shareholders

    N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Delivering value for shareholders

  29. Slide 29: Strong Growth in Net Sales

    N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Strong Growth in Net Sales

  30. Slide 30: Strong Growth in Backlog

    N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Strong Growth in Backlog

  31. Slide 31: Growth in Revenues

    N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Growth in Revenues * Peer Group includes PPD, Parexel, PRA and ICON for 2004-2006. 2007 and 2008 excludes PRA. **Includes acquisition of Charles River Laboratories Clinical Services (CRLCS) as of

  32. Slide 32: Operating Margin Comparison

    N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a Operating Margin Comparison *Peer Group includes PPD, Parexel, PRA and ICON for 2004-2006. 2007 and 2008 exclude PRA. ** Proforma operating margin for full year 2006 excludes charges for stock opt

  33. Slide 33: 2008 Guidance

    N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a 2008 Guidance * Amounts in Millions

  34. Slide 34: Summary for Q3

    Kendle Real people Real sults? Summary for Q3 + At the current Street consensus; Consensus is $126.9M + At or above current Street consensus; Consensus is $0.56

  35. Slide 35: r i c a

    N o r t h A m e r i c a • E u r o p e • A s i a / P a c i f i c • L a t i n A m e r i c a • A f r i c a

Kendle International — UBS Global Life Sciences Conference 2008 on 6ix